Therapy News and Research

RSS

Maternal antiviral suppressive therapy may not be as effective as thought

Maternal antiviral suppressive therapy does not necessarily prevent the development of neonatal herpes simplex virus disease, warn researchers in The Journal of Pediatrics.

9 Jul 2012

UMHC acquires MicroThermX Microwave Ablation System

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has sold a MicroThermX Microwave Ablation System to the University of Miami Hospital and Clinics to include the Sylvester Comprehensive Cancer Center and the University of Miami Hospital.

9 Jul 2012

Enrollment complete in Lux Biosciences Luveniq Phase 3 study for non-infectious uveitis

Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.

9 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.

9 Jul 2012

Novel treatment for cancer based on protein from HIV-1 virus

Yissum, Research and Development Company of the Hebrew University of Jerusalem, introduces a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1). The method was invented by Professor Emeritus Moshe Kotler and Dr. Roni Nowarski from the Department of Immunology and Cancer Research at the Hebrew University.

9 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Long Beach Memorial uses Toshiba's Aquilion ONE to expand stroke care capabilities

To expand its stroke care capabilities for fast diagnoses and more accurate treatment, Long Beach Memorial, a primary stroke care center for MemorialCare Health System, is using Toshiba's Aquilion ONE dynamic volume CT system for both acute stroke diagnoses and interventional planning.

9 Jul 2012

PsiOxus closes Series B round of equity financing

PsiOxus Therapeutics, Ltd. announced that it has closed a Series B round of equity financing totaling £22 million ($34 million).

9 Jul 2012

Novel gene therapy approach may treat dysferlinopathies

The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.

9 Jul 2012

Researchers describe inflammatory mechanism of sunburn

The biological mechanism of sunburn - the reddish, painful, protective immune response from ultraviolet (UV) radiation - is a consequence of RNA damage to skin cells, report researchers at the University of California, San Diego School of Medicine and elsewhere in the July 8, 2012 Advance Online Publication of Nature Medicine.

9 Jul 2012

High expression of interleukin-9 in immune cells inhibits melanoma growth

Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.

9 Jul 2012

Effect of spaceflight on C. elegans could help it to live longer

The effect of spaceflight on a microscopic worm - Caenorhabditis elegans (C. elegans) - could help it to live longer.

8 Jul 2012

Presence of SPDEF protein may predict prostate cancers that are unable to metastasize

Prostate cancer doesn't kill in the prostate - it's the disease's metastasis to other tissues that can be fatal. A University of Colorado Cancer Center study published this week in the Journal of Biological Chemistry shows that prostate cancer cells containing the protein SPDEF continue to grow at the same pace as their SPDEF- cousins, but that these SPDEF+ cells are unable to survive at possible sites of metastasis.

8 Jul 2012

New Gateway-funded phase II ADAPT study for metastatic colorectal cancer

The Gateway for Cancer Research announces an exciting new Gateway-funded phase II study using ADAPT therapy for treatment of metastatic colorectal cancer based on a 2010 AACR presentation by Dr. Lin and his collaborators.

7 Jul 2012

FDA approves KRAS gene mutation test for colorectal cancer

The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).

7 Jul 2012

New optical microscope identifies rare breast cancer cells

The ability to distinguish and isolate rare cells from among a large population of assorted cells has become increasingly important for the early detection of disease and for monitoring disease treatments.

7 Jul 2012

NewYork-Presbyterian/WCMC first in N.Y. City to offer INTRABEAM radiotherapy

NewYork-Presbyterian Hospital/Weill Cornell Medical Center is the first and only hospital in the five boroughs of New York City to offer women with early stage breast cancer INTRABEAM radiotherapy, an innovative radiation treatment delivered in a single dose at the time of surgery.

6 Jul 2012

ADCT, CRT sign agreements to develop ADCs against cancer

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT's 'warhead' and linker chemistries.

6 Jul 2012

Roche receives FDA approval for CMV viral load test

The U.S. Food and Drug Administration today approved the first DNA test to help health care professionals gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.

6 Jul 2012